面对新NIFTP分类的甲状腺结节诊断标志物:是时候重新设定了?
该综述探讨甲状腺分子检测在细针穿刺(FNA)细胞学不确定或可疑结节鉴别诊断中的临床有效性,面临机构间癌症患病率差异及新NIFTP分类的挑战。NIFTP既往被归为恶性,现有分子panel均在将其视为恶性的背景下验证。综述分析NIFTP重新分类为癌前病变对原始验证研究的影响,以及甲状腺癌患病率显著差异对检测性能的影响。
要点
- 当前甲状腺分子检测针对FNA细胞学不确定或可疑结节的鉴别诊断设计。
- NIFTP既往被归为恶性,现有分子panel均在此背景下验证。
- 机构间甲状腺癌患病率差异及NIFTP新分类对检测临床有效性构成挑战。
核心结论
- 综述分析NIFTP重新分类为癌前病变对原始验证研究可能的影响,并探讨甲状腺癌患病率显著差异对检测性能的影响。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 现有甲状腺分子检测针对FNA细胞学不确定或可疑结节的鉴别诊断设计。
- 机构间癌症患病率存在差异,且新出现NIFTP分类。
- NIFTP既往被归为恶性,现有市场分子panel均在将其视为恶性的背景下验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current thyroid molecular tests are specifically designed for the differential diagnosis of nodules with indeterminate or suspicious fine-needle aspiration (FNA) cytology. SUMMARY: However, their clinical validity faces challenges from both variation among institutions in cancer prevalence and, most recently, the new category of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The latter diagnosis was previously classified as malignant. Relevant to this, all molecular panels on the market today were originally tested and validated within the context of these entities being considered malignant. CONCLUSION: This review examines possible effects of the NIFTP reclassification as a precancerous lesion on the original validation studies and, investigates the effect of the significant reported variability in thyroid cancer prevalence on the performance of these tests.
引用
- Sahli ZT, Umbricht CB, Schneider EB, et al. Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset? Thyroid. 2017. PMID: 28859553. doi:10.1089/thy.2017.0238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。